Shariat - Figure 29
Photodynamic Diagnosis and Progression
FIG. 29: An analysis by Kamat et al[36] of a long-term follow-up study of blue-light cystoscopy with hexaminolevulinate in patients with NMI bladder cancer[37] reported that PDD significantly decreased progression rate compared with white light cystoscopy at 12 months (5.9% vs 8.8%, respectively) and at 36 months (10.2% vs 14.6%) (Figure).
References
Kamat AM, Cookson M, Witjes JA, et al. The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer - a new analysis. Bladder Cancer. 2016;2:273−8 https://dx.doi.org/10.3233%2FBLC-160048
Grossman HB, Stenzl A, Fradet Y, et al. Long-term reduction in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58−62 http://dx.doi.org/10.1016/j.juro.2012.03.007
